Obesity Drug Pipeline 2026-2027: What’s Coming, and When You Can Really Get It

What Do “Phase 3,” “Estimand,” and the Other Terms Mean?

Quick answer: A drug in the “pipeline” is still in testing and not approved to sell. “Phase 3” is usually the big final testing stage. An “estimand” is just how a trial measures its result — the same trial can report two different weight-loss numbers, and we always show both.

Pipeline (on this page)

Obesity drugs still in clinical testing and not FDA-approved for everyday prescribing.

Investigational

Same idea. It's in trials. You can't get it from a regular pharmacy.

Phase 2 / Phase 3

Stages of human testing. Phase 3 is usually the large final stage. Finishing Phase 3 does not guarantee a company will file or that the FDA will approve.

NDA

A company formally asking the FDA to approve a drug. Filing is not the same as approval.

FDA action date

A public target date for the FDA's decision, when one exists. Most pipeline drugs don't have a public one.

Estimand

Trials report results two ways. "Stuck-with-it" counts people who stayed on the drug; "counting everyone" counts all participants, including those who quit early. Neither is the "real" number -- they answer different questions. We show both.

What Does the Obesity Drug Pipeline 2026-2027 Look Like Right Now?

Quick answer: We track 13 major investigational obesity drugs, from “filed with the FDA” to “years away,” plus three recently approved options shown separately. For each one we label how sure the date is — an actual FDA fact, a company’s own forecast, or just a trial estimate. A drug in the 2027 column means a trial or filing is expected then. It does not mean it’ll be in pharmacies in 2027.

What’s Already Approved and Available Right Now?

Quick answer: Three FDA-approved options arrived in the last seven months: the Wegovy pill (oral semaglutide, December 2025), Foundayo (orforglipron, April 2026), and Wegovy HD (a higher-dose 7.2 mg semaglutide shot, March 2026).

Here’s why this matters more than any 2027 rumor: some people put off treatment waiting for the “perfect” future drug — and the milestones many were waiting on already landed.

↑ Back to full tracker

Which Obesity Drug Is Closest to FDA Approval?

Quick answer: CagriSema is closest, because it’s the only drug here whose U.S. application is already filed and under review. Retatrutide and survodutide have positive final-stage data, but neither has an announced U.S. filing or FDA decision date.

CagriSema — filed, and the only near-term decision

CagriSema is an investigational once-weekly shot combining semaglutide (the GLP-1 in Wegovy) plus the investigational amylin drug cagrilintide. Novo Nordisk filed its application with the FDA in December 2025 and expects a U.S. decision in Q4 2026. In REDEFINE 1, people lost about 20.4% counting everyone, or 22.7% among those who stuck with it, over 68 weeks. The honest part: in the REDEFINE 4 head-to-head trial, CagriSema produced 23% weight loss at 84 weeks versus 25.5% for tirzepatide (the medicine in Zepbound) — and it did not meet its goal of proving it wasn’t inferior to tirzepatide. Strong drug, genuinely close to approval — but not the unchallenged leader.

→ Full CagriSema availability guide · CagriSema vs. Zepbound · CagriSema side effects

Retatrutide — the data is stunning, the date isn’t set

Retatrutide hits GLP-1, GIP, and glucagon (triple). In the pivotal TRIUMPH-1 trial, people lost an average of 28.3% among those who stuck with it (or 25.0% counting everyone) over 80 weeks at the top 12 mg dose. A prespecified extension showed 30.3% at 104 weeks among those with a starting BMI of 35 or higher. Reality check: as of now, Lilly has not announced a U.S. filing date or an FDA decision date. Anyone telling you “retatrutide launches in 2027” is guessing.

Survodutide — positive data, plus a benefit for the liver

Survodutide (Boehringer Ingelheim / Zealand Pharma) hits GLP-1 and glucagon. In SYNCHRONIZE-1, people lost up to 16.6% among those who stuck with it over 76 weeks, with strong fat- and liver-related results. The maker has said the program may support a 2026 filing — but there’s no announced FDA decision date.

↑ Back to full tracker

Which “2027 Drugs” Are Really Just Trial Readouts?

Quick answer: MariTide and VK2735 have meaningful 2027 trial-completion windows, and several other drugs are moving through Phase 3. Those milestones could eventually lead to FDA filings, but none is a confirmed 2027 U.S. launch.

MariTide — the investigational monthly shot

Amgen’s MariTide stands out for convenience: designed as a shot you take once a month, or even less often, instead of weekly. In Phase 2, people lost up to 19.9% among those who stuck with it (or 16.2% counting everyone) over a year. Its big Phase 3 program (MARITIME) runs into 2027. So it’s a genuinely exciting 2027 data story — not a 2027 pharmacy story.

VK2735 — a shot and a pill from a smaller player

Viking Therapeutics’ VK2735 hits GLP-1 and GIP. The weekly shot is in Phase 3 (VANQUISH trials), which Viking expects to complete in 2027. The pill is a separate, earlier program heading to Phase 3 in H2 2026. Early Phase 2 numbers for the shot looked promising (up to 14.7% in just 13 weeks), but a 13-week number can’t be stretched to predict a final result.

The rest of the Phase 3 field

• Zenagamtide (Novo’s drug formerly called amycretin) — GLP-1/amylin in pill and shot form. Up to 24.3% at 36 weeks (early data). Phase 3 started 2026.
• Eloralintide (Eli Lilly) — selective amylin weekly shot, up to ~20% in Phase 2. Phase 3 runs to around 2030 — a reminder that “in Phase 3” doesn’t always mean “coming soon.”
• Berobenatide (Pfizer, formerly MET-097i) — long-acting GLP-1 weekly shot with a monthly-maintenance study. Phase 3 starting 2026; Pfizer has stated a goal of a first approval around 2028.
• Enicepatide (Roche, formerly CT-388) — GLP-1/GIP weekly shot. ~22.5% placebo-adjusted in Phase 2; Phase 3 (ENITH1/ENITH2) started Q1 2026.
• Cagrilintide on its own — the amylin half of CagriSema, also in standalone Phase 3 with ~11.8% in the REDEFINE 1 monotherapy arm.

↑ Back to full tracker

What Oral (Pill) Obesity Drugs Are Coming?

Quick answer: Beyond the two pills already approved, the notable investigational oral drugs are aleniglipron, an oral version of VK2735, and oral zenagamtide. They’re at different stages, and none is an approved shortcut yet.

The needle-free crowd is the reason pills matter so much — a lot of people simply won’t do a weekly injection.

• Aleniglipron (Structure Therapeutics) — once-daily GLP-1 pill. Up to 16.3% at 44 weeks (Phase 2). Phase 3 expected Q3 2026.
• Oral VK2735 (Viking) — the pill version of VK2735, heading to Phase 3 in H2 2026.
• Oral zenagamtide (Novo) — GLP-1/amylin pill form, Phase 3 but on a longer timeline.

↑ Back to full tracker

How Do GLP-1, GIP, Glucagon, and Amylin Pipeline Drugs Differ?

Quick answer: These drugs target different appetite, fullness, blood-sugar, and energy pathways, and many hit more than one at once. Hitting more targets does not automatically make a drug safer or better.

↑ Back to full tracker

Which Investigational Drug Shows the Most Weight Loss?

Quick answer: By the raw headline, retatrutide leads at 28.3% over 80 weeks among people who stuck with it (25.0% counting everyone). But no trial compared all these drugs head-to-head under the same rules, so the biggest number is not automatically the “best” drug for you.

Why you can’t just rank by percentage: a Phase 2 number isn’t the same as a Phase 3 number; a 13-week result can’t be compared to a 68- or 80-week one; trials that include people with diabetes often show smaller averages; and the estimand matters.

These are not head-to-head results. Different trials, lengths, doses, and patient groups. Treat this as a map of the landscape — not a leaderboard.

↑ Back to full tracker

Are Monthly Shots or Fewer Injections Really Coming?

Quick answer: MariTide and berobenatide are the clearest programs testing monthly or less-frequent dosing, and VK2735 is studying maintenance schedules. All of it is still investigational.

A monthly schedule would cut scheduled injections from 52 a year down to 12. That’s a real difference — but whether it actually improves adherence hasn’t been established for these investigational programs yet. MariTide is furthest along on the monthly idea. Berobenatide is testing a weekly start with a monthly-maintenance study. VK2735 is exploring maintenance dosing too. Promising — but “being studied” is not “proven,” so hold the excitement until the results and the FDA label are in.

What Are the Biggest Risks and Unknowns?

Quick answer: Every investigational drug still faces real uncertainty — approval isn’t guaranteed, the final label can change, and long-term safety, side effects, price, and insurance coverage are unknown until launch.

Can I Buy Retatrutide, CagriSema, or These Other Drugs Now?

Quick answer: No. None of these investigational drugs is an FDA-approved product you can get through normal prescribing. Legitimate access is a real clinical trial. And the FDA has stated plainly that retatrutide and cagrilintide cannot be used in compounding under federal law — they are not part of any approved drug.

Know the four different categories:

We keep FDA-approved and compounded options strictly separate: they are different things. If you want treatment now, your legitimate choices are an FDA-approved medicine or a real, registered clinical trial.

How Do I Find or Join a Clinical Trial?

Quick answer: Search ClinicalTrials.gov by the drug’s current name and its study name, filter to “recruiting,” and check that a study has a location you can reach and a real contact. Joining is voluntary, you might not qualify, and you might get a placebo.

Should I Wait for a 2027 Drug — or Start Now?

Quick answer: A future release date, by itself, is not a good reason to delay care you may need today. The smart choice depends on your health, whether an approved option fits, your access and budget, whether you’d qualify for a trial, and your clinician’s advice.

How Did The RX Index Verify the Obesity Drug Pipeline 2026-2027?

Quick answer: We rank FDA records, ClinicalTrials.gov, peer-reviewed studies, and dated company announcements above everything else, and we label each date by how we know it. We leave analyst guesses and unsourced “release dates” out of the verified columns.

Our source order: (1) the FDA’s own approvals and safety notices, (2) ClinicalTrials.gov, (3) peer-reviewed journal results, (4) official company and investor announcements, (5) major medical and payer organizations for context. Forums and social media? Only to understand how people talk about this — never as proof.

We update this page monthly, and after any major FDA, company, or trial news, and we update the “Last verified” date when we do.

What Could Change This Tracker Next?

Quick answer: The biggest update triggers are an FDA decision on CagriSema, a retatrutide or survodutide filing, new Phase 3 results, changes to trial dates, and drug name changes. We update this page when a source changes a real fact — not to fake freshness.

Watch for: the FDA accepting or acting on an application; a company announcing it filed; new trial results; a trial’s completion date moving; or a program getting paused. After a drug is approved, we’ll add the brand name, dose, price, and coverage. Until then, we won’t pretend to know those.

Frequently Asked Questions

Verified against FDA records, ClinicalTrials.gov, and company announcements as of July 15, 2026.

When will retatrutide be FDA approved?

As of July 15, 2026, there's no announced U.S. filing date or FDA decision date. Eli Lilly has strong Phase 3 results (TRIUMPH-1), but no reliable access year can be stated until it files, the FDA accepts the application, and a review timeline becomes public.

Is CagriSema FDA approved?

No. It's under FDA review. Novo Nordisk filed in December 2025 and expects a U.S. decision in Q4 2026. That's the company's forecast, not an official FDA decision date.

What obesity drug could be approved in 2026?

CagriSema is the clearest candidate, because its application is already under review with a Q4 2026 decision expected. Approval is never guaranteed until the FDA acts.

Is survodutide available yet?

No. It's still investigational. Its Phase 3 trial showed up to 16.6% weight loss and strong results for fat and liver measures, but it isn't an approved product you can get through a normal prescription.

Is MariTide a monthly injection?

Yes -- it's being developed as a once-monthly (or less frequent) shot, and it's in Phase 3. That schedule is still investigational and the final approved dosing could differ.

Is VK2735 a pill or a shot?

Both are being developed, but the weekly shot is further along (Phase 3). Results and timing for one form don't automatically apply to the other.

What is zenagamtide?

The current name for the Novo Nordisk drug formerly called amycretin -- a single molecule that hits GLP-1 and amylin, being developed as both a pill and a shot.

What is berobenatide?

The current name for Pfizer's drug formerly called MET-097i -- a long-acting GLP-1 being developed as a weekly shot with a separate monthly-maintenance study, now entering Phase 3.

Are trial completion dates the same as FDA approval dates?

No. A trial finishing is followed by data analysis, a possible FDA filing, FDA review, and only then a possible approval. Each step can add many months.

Which pipeline drug shows the most weight loss?

Retatrutide has the biggest raw headline (28.3% stuck-with-it, 25.0% counting everyone), but that's not a head-to-head win over every other drug, and the number depends on how it's measured.

Can retatrutide or cagrilintide be compounded?

No. The FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any use.

Can I buy these drugs from a "research peptide" website?

You shouldn't. A vial labeled with a drug's name isn't proof of what's inside, how it was made, or its strength. The FDA warns these unapproved products can be harmful. Use an FDA-approved medicine or a real, registered clinical trial instead.

How often is this page updated?

We do a full source check monthly, plus updates whenever the FDA, a drug company, or a trial registry changes a real milestone.

Should I wait for a future drug?

That depends on your health needs, whether approved options fit, your access, trial eligibility, and your clinician's advice. A forecasted date alone isn't a good reason to delay care.